Table 3

Efficacy and safety outcomes stratified by age

Outcomes	Age	n/N (%)	HR/OR (95% CI)*	Log-rank p value
Efficacy outcomes
Stroke	<65	207/3251 (6.4)	---	---
	65–80	188/2755 (6.8)	0.98 (0.79 to 1.20)	0.82
	≥80	39/406 (9.6)	1.39 (0.96 to 2.02)	0.08
Stroke within 30 days	<65	172/3251 (5.3)	---	---
	65–80	156/2755 (5.7)	1.01 (0.80 to 1.26)	0.96
	≥80	33/406 (8.1)	1.45 (0.97 to 2.18)	0.07
Ischaemic stroke	<65	203/3251 (6.2)	---	---
	65–80	186/2755 (6.8)	0.98 (0.80 to 1.21)	0.85
	≥80	38/406 (9.4)	1.37 (0.94 to 1.99)	0.10
Composite vascular events†	<65	246/3251 (7.6)	---	---
	65–80	229/2755 (8.3)	1.00 (0.83 to 1.21)	0.97
	≥80	47/406 (11.6)	1.41 (1.00 to 1.98)	0.048
Disabling stroke‡	<65	82/3251 (2.5)	---	---
	65–80	78/2755 (2.8)	1.05 (0.76 to 1.46)	0.75
	≥80	29/406 (7.1)	2.43 (1.52 to 3.88)	0.0002
Safety outcomes
Severe or moderate bleeding	<65	7/3251 (0.2)	---	---
	65–80	9/2755 (0.3)	1.78 (0.63 to 5.05)	0.28
	≥80	4/406 (1.0)	8.40 (1.95 to 36.21)	0.004
Any bleeding	<65	138/3251 (4.2)	---	---
	65–80	94/2755 (3.4)	0.81 (0.62 to 1.07)	0.14
	≥80	18/406 (4.4)	0.99 (0.59 to 1.68)	0.98
Intracranial haemorrhage	<65	5/3251 (0.2)	---	---
	65–80	2/2755 (0.1)	0.47 (0.08 to 2.72)	0.45
	≥80	2/406 (0.5)	2.86 (0.41 to 20.17)	0.29
Mortality	<65	9/3251 (0.3)	---	---
	65–80	12/2755 (0.4)	1.39 (0.55 to 3.50)	0.49
	≥80	6/406 (1.5)	7.56 (2.23 to 25.70)	0.001

*Adjusted for sex, medical history (hypertension, diabetes mellitus, dyslipidaemia, previous ischaemic stroke), current smoking and drinking, median time to randomisation, and previous antiplatelet therapy and lipid-lowering therapy.
†Composite vascular events included ischaemic stroke, haemorrhagic stroke, transient ischaemic stroke, myocardial infarction or death from vascular causes.
‡A stroke was defined as disabling if the patient had a modified Rankin scale score of >1.